Last reviewed · How we verify
TP-1454 monotherapy
At a glance
| Generic name | TP-1454 monotherapy |
|---|---|
| Sponsor | Sumitomo Pharma America, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1 Study of Oral TP-1454 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TP-1454 monotherapy CI brief — competitive landscape report
- TP-1454 monotherapy updates RSS · CI watch RSS
- Sumitomo Pharma America, Inc. portfolio CI